AR093937A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
AR093937A1
AR093937A1 ARP130104648A ARP130104648A AR093937A1 AR 093937 A1 AR093937 A1 AR 093937A1 AR P130104648 A ARP130104648 A AR P130104648A AR P130104648 A ARP130104648 A AR P130104648A AR 093937 A1 AR093937 A1 AR 093937A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
chemical compounds
och3
chf2
Prior art date
Application number
ARP130104648A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AR093937A1 publication Critical patent/AR093937A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Los derivados de imidazopiridazina de la presente modulan la actividad del receptor GABAA. Son útiles para el tratamiento de diversas afecciones, por ejemplo, el dolor. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) en donde R¹ se selecciona de alquilo C₁₋₄, cicloalquilo C₃₋₄, NH₂ y NH-alquilo C₁₋₄, y R² es H; o R¹ y R² juntos son -CH₂-CH₂- o -N(CH₃)-CH₂-; R³ se selecciona de H, F, CHF₂, OCH₃ y CN; R⁴ se selecciona de H, F, Cl, OH, OCH₃ y CN; y R⁵ se selecciona de alquilo C₂₋₄, cicloalquilo C₃₋₅ y cicloalquilo C₃₋₅ sustituido con metilo; o una sal de aquel aceptable desde el punto de vista farmacéutico.
ARP130104648A 2012-12-14 2013-12-12 Compuestos quimicos AR093937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737157P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
AR093937A1 true AR093937A1 (es) 2015-07-01

Family

ID=49880883

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104648A AR093937A1 (es) 2012-12-14 2013-12-12 Compuestos quimicos

Country Status (44)

Country Link
US (3) US8952008B2 (es)
EP (1) EP2938615B1 (es)
JP (1) JP5869740B2 (es)
KR (1) KR101746314B1 (es)
CN (1) CN104837843B (es)
AP (1) AP2015008526A0 (es)
AR (1) AR093937A1 (es)
AU (1) AU2013356894B2 (es)
BR (1) BR112015014097B1 (es)
CA (1) CA2892174C (es)
CL (1) CL2015001652A1 (es)
CR (1) CR20150254A (es)
CU (1) CU24338B1 (es)
CY (1) CY1118568T1 (es)
DK (1) DK2938615T3 (es)
DO (1) DOP2015000147A (es)
EA (1) EA025635B1 (es)
EC (1) ECSP15029822A (es)
ES (1) ES2608640T3 (es)
GE (1) GEP201706710B (es)
GT (1) GT201500159A (es)
HK (1) HK1209743A1 (es)
HR (1) HRP20161559T1 (es)
HU (1) HUE032400T2 (es)
IL (1) IL239243A0 (es)
LT (1) LT2938615T (es)
MA (1) MA38112B1 (es)
MD (1) MD4651B1 (es)
ME (1) ME02566B (es)
MX (1) MX366023B (es)
NI (1) NI201500081A (es)
PE (1) PE20151163A1 (es)
PH (1) PH12015501293A1 (es)
PL (1) PL2938615T3 (es)
PT (1) PT2938615T (es)
RS (1) RS55307B1 (es)
SG (1) SG11201503735YA (es)
SI (1) SI2938615T1 (es)
TN (1) TN2015000261A1 (es)
TW (1) TWI478926B (es)
UA (1) UA112028C2 (es)
UY (1) UY35185A (es)
WO (1) WO2014091368A1 (es)
ZA (1) ZA201504226B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2664810T3 (es) * 2014-06-12 2018-04-23 Pfizer Limited Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA
JP6625610B2 (ja) 2014-07-31 2019-12-25 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se ピラゾールの調製方法
MX2017014287A (es) 2015-05-11 2018-03-07 Basf Se Proceso para preparar 4-amino-piridazinas.
US10538523B2 (en) * 2015-12-10 2020-01-21 Pfizer Limited 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
WO2018055550A1 (en) * 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
JOP20190053A1 (ar) * 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
KR20200003047A (ko) 2017-05-02 2020-01-08 바이엘 악티엔게젤샤프트 해충 방제제로서의 2-(헤트)아릴-치환된 축합된 비시클릭 헤테로시클릭 유도체
CN117695287A (zh) * 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN116693555A (zh) * 2022-02-25 2023-09-05 上海赛默罗生物科技有限公司 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
CN117069725A (zh) * 2022-05-10 2023-11-17 上海赛默罗生物科技有限公司 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
AU2002212530B2 (en) 2000-11-10 2006-08-17 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for GABA receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
CA2555263A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US20080132510A1 (en) 2005-01-21 2008-06-05 Bingsong Han Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
CN102596961B (zh) * 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1,2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
ES2526675T3 (es) * 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje

Also Published As

Publication number Publication date
IL239243A0 (en) 2015-07-30
US20150259352A1 (en) 2015-09-17
PH12015501293B1 (en) 2015-08-24
US20140171435A1 (en) 2014-06-19
US20150105396A1 (en) 2015-04-16
GT201500159A (es) 2015-09-23
PL2938615T3 (pl) 2017-04-28
ZA201504226B (en) 2016-06-29
EP2938615B1 (en) 2016-10-26
LT2938615T (lt) 2016-12-27
TW201434840A (zh) 2014-09-16
CL2015001652A1 (es) 2015-08-14
CN104837843A (zh) 2015-08-12
BR112015014097B1 (pt) 2022-11-29
JP5869740B2 (ja) 2016-02-24
CU24338B1 (es) 2018-04-03
EP2938615A1 (en) 2015-11-04
CU20150058A7 (es) 2015-11-27
PT2938615T (pt) 2016-12-26
HUE032400T2 (hu) 2017-09-28
US8952008B2 (en) 2015-02-10
BR112015014097A2 (pt) 2019-12-17
SG11201503735YA (en) 2015-07-30
HK1209743A1 (zh) 2016-04-08
TN2015000261A1 (fr) 2016-10-03
AP2015008526A0 (en) 2015-06-30
KR20150088877A (ko) 2015-08-03
KR101746314B1 (ko) 2017-06-12
ECSP15029822A (es) 2017-08-31
MD20150051A2 (ro) 2015-09-30
ES2608640T3 (es) 2017-04-12
MA38112A1 (fr) 2018-03-30
PH12015501293A1 (en) 2015-08-24
WO2014091368A1 (en) 2014-06-19
EA025635B1 (ru) 2017-01-30
CA2892174A1 (en) 2014-06-19
MX366023B (es) 2019-06-24
AU2013356894B2 (en) 2015-11-12
CR20150254A (es) 2015-07-09
CA2892174C (en) 2018-02-06
PE20151163A1 (es) 2015-08-14
TWI478926B (zh) 2015-04-01
AU2013356894A1 (en) 2015-05-28
MD4651B1 (ro) 2019-09-30
CN104837843B (zh) 2016-08-31
HRP20161559T1 (hr) 2016-12-30
MA38112B1 (fr) 2018-10-31
JP2016503001A (ja) 2016-02-01
DK2938615T3 (da) 2017-01-02
MX2015007598A (es) 2015-10-22
NI201500081A (es) 2015-09-16
EA201590761A1 (ru) 2015-12-30
SI2938615T1 (sl) 2017-02-28
ME02566B (me) 2017-02-20
UA112028C2 (uk) 2016-07-11
DOP2015000147A (es) 2015-09-15
RS55307B1 (sr) 2017-03-31
UY35185A (es) 2014-07-31
GEP201706710B (en) 2017-07-25
CY1118568T1 (el) 2017-07-12

Similar Documents

Publication Publication Date Title
AR093937A1 (es) Compuestos quimicos
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR098912A1 (es) Inhibidores de syk
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
CO7400871A2 (es) Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
AR098522A1 (es) Compuesto de triazolo-piridina
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR089550A1 (es) Compuestos quimicos
AR116283A1 (es) Inhibidores del sarcómero cardíaco
CY1122744T1 (el) Ενωσεις τετρακυκλινης
BR112013021941A2 (pt) agente terapêutico para tumor
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR088774A1 (es) Compuesto de 7-[3,5-dihidroxi-2-(3hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) y su uso para preparar una composicion farmaceutica para inducir el crecimiento de pelo en un humano
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR091490A1 (es) Antagonistas de iap
EA201492255A1 (ru) Феноксиэтилпиперидиновые соединения
AR084173A1 (es) Derivados oxazolil-metileter como agonistas del receptor alx

Legal Events

Date Code Title Description
FB Suspension of granting procedure